A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200mg oral fluconazole in Blantyre, Malawi

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Gaskell, Katherine M ^a,b   Rothe, Camilla ^a,c   Gnanadurai, Roshina ^a,c   Goodson, Patrick ^a,c   Jassi, Chikondi ^a   Heyderman, Robert S ^a,b   Allain, Theresa J ^a,c   Harrison, Thomas S ^d   Lalloo, David G ^a,b   Sloan, Derek J ^a,b,e   Feasey, Nicholas A ^a,b  

^a UNIVERSITY OF MALAWI   (Malawi)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c QUEEN ELIZABETH CENTRAL HOSPITAL   (Malawi)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ANTIFUNGAL AGENT;

ADULT; CLINICAL ARTICLE; CRYPTOCOCCAL MENINGITIS; DEATH; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTRACRANIAL PRESSURE; LUMBAR PUNCTURE; MALAWI; MALE; MONOTHERAPY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROSPECTIVE STUDY; REVIEW; SURVIVAL; TREATMENT DURATION; AIDS-RELATED OPPORTUNISTIC INFECTIONS; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; MENINGITIS, CRYPTOCOCCAL; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; FEMALE; FLUCONAZOLE; HIV-1; HUMANS; MALAWI; MALE; MENINGITIS, CRYPTOCOCCAL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84910656554     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110285     Document Type: Review

References (17)

1. Jarvis JN, Harrison TS (2007) HIV-associated cryptococcal meningitis. AIDS 21: 2119-2129.
2. Park BJ, Wannemuehler KA, Marston B.J., Govender N., Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
3. Wall EC ED, Mukaka M, Bar-Zeev N, Feasey N., Jahn A, et al. (2014) Bacterial meningitis in Malawian adults, adolescents and children during the era of antiretroviral scale-up and Hib vaccination (2000-2012). CID In press (manuscript number 73218R2).
4. van der Horst CM, Saag MS, Cloud G.A., Hamill RJ, Graybill JR, et al. (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337: 15-21.
5. Perfect JR, Dismukes WE, Dromer F, Goldman D.L., Graybill JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 50: 291-322.
6. Loyse A, Thangaraj H, Easterbrook P., Ford N, Roy M, et al. (2013) Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis 13: 629-637.
7. Brouwer AE, Rajanuwong A, Chierakul W., Griffin GE, Larsen RA, et al. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363: 1764-1767.
8. Rothe C, Sloan DJ, Goodson P, Chikafa J., Mukaka M, et al. (2013) A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800mg oral fluconazole in Blantyre, Malawi. PLoS One 8: e67311.
9. MOH (2011) Clinical Management of HIV in children and adults. Malawi Integrated Guidelines. Ministry of Health Malawi.
10. Longley N, Muzoora C, Taseera K., Mwesigye J, Rwebembera J, et al. (2008) Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 47: 1556-1561.
11. Sudan A, Livermore J, Howard S.J., Al-Nakeeb Z, Sharp A, et al. (2013) Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. Antimicrob Agents Chemother 57: 2793-2800.
12. Sloan DJ, van Oosterhout JJ, Malisita K, Phiri EM, Lalloo D.G., et al. (2013) Evidence of improving antiretroviral therapy treatment delays: an analysis of eight years of programmatic outcomes in Blantyre, Malawi. BMC Public Health 13: 490.
13. Rugemalila J, Maro VP, Kapanda G, Ndaro A.J., Jarvis JN (2013) Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay. Trop Med Int Health 18: 1075-1079.
14. Meya DB, Manabe YC, Castelnuovo B, Cook B.A., Elbireer AM, et al. (2010) Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or =100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 51: 448-455.
15. Jarvis JN, Harrison TS, Lawn S.D., Meintjes G., Wood R, et al. (2013) Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One 8: e69288.
16. de Vedia L, Arechavala A, Calderon M.I., Maiolo E., Rodriguez A, et al. (2013) Relevance of intracranial hypertension control in the management of Cryptococcus neoformans meningitis related to AIDS. Infection 41: 1073-1077.
17. Wijewardana I, Jarvis JN, Meintjes G, Harrison T.S., Bicanic T (2011) Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. J Infect 63: 484-486.